Find Your Funding Opportunity

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
Bookmarked grants will display in your Account Setting page

Service Source Final Application Due Date Funding Available Match Required
Health Care Federal
02-28-2024 N/A No Match
  • Service
  • Source
  • Final Application Due Date
  • Funding Available
  • Match Required
  • Past
  • Current
  • Forecasted
    • Opportunity Type Discretionary
    • CFDA

      93.233 -- National Center on Sleep Disorders Research

      93.350 -- National Center for Advancing Translational Sciences

      93.837 -- Cardiovascular Diseases Research

      93.838 -- Lung Diseases Research

      93.839 -- Blood Diseases and Resources Research

      93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders


    The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.

    • IHE
    • Local Government
    • Non-Profit
    • Other
    • State Government
    • Tribal Government
    Additional Eligibility Information

    Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

    Key Date(s)
    • November 16, 2021: Posted Date
    • November 17, 2021: Last Updated Date
    • February 28, 2024: Current Closing Date for Applications
    • February 28, 2024: Application Due Date
    • April 04, 2024: Application Archive Date
    Contact Information

    NIH OER Webmaster


    Feedback Feedback

    Your opinion is important to us

    • How would you rate your overall experience on our website?

    • How easy is it to find the information you need?

    • How do you rate the look & feel of our website?

    • How could we improve our website?